Metpil A 50 Tablet SR is a combination antihypertensive medication containing Amlodipine 5 mg and Metoprolol Succinate 47.5 mg. Amlodipine, a calcium channel blocker, acts by inhibiting calcium ion influx into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance, thereby lowering blood pressure. Metoprolol Succinate, a selective beta-1 adrenergic receptor blocker, decreases heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction and improved cardiac function. This sustained-release formulation ensures a gradual and consistent release of active ingredients, promoting stable plasma concentrations and enhancing patient compliance through once-daily dosing. Metpil A 50 Tablet SR is indicated for the management of essential hypertension and angina pectoris, particularly in patients requiring combination therapy for optimal blood pressure control and symptom relief. It may also be beneficial in reducing the risk of cardiovascular events in patients with ischemic heart disease. Caution is advised in patients with bradycardia, heart block, or severe hepatic impairment. Common adverse effects include dizziness, fatigue, and peripheral edema. Regular monitoring of blood pressure, heart rate, and renal function is recommended during therapy to ensure efficacy and safety.